Leukemia

University of Arkansas publishes research in hematologic disease therapy

Leukemia Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

"The patient did not respond to cytosine arabinoside 100 mg/m² continuous infusion over 7 days with daunorubicin 45 mg/m² daily for 3 days. He also did not respond to salvage induction therapy with gemtuzumab (6 mg/m² on day 1 and 4 mg/m² on day 8) and intravenous continuous infusion cytosine arabinoside 200 mg/m². We review other cases of lymphoma and leukemia associated with tumor necrosis factor inhibitors and suggest mechanisms by which inhibition of the TNF-alpha family may predispose to cancer," wrote B. Nair and colleagues, University of Arkansas.

The researchers concluded: "We also suggest that all patients being considered for TNF-alpha treatment be screened for hematologic malignancies or premalignancies with blood counts and bone marrow aspirates/biopsies if indicated."

Nair and colleagues published their study in American Journal of Hematology (TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. American Journal of Hematology, 2007;82(11):1022-4).

For additional information, contact B. Nair, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Oncology, Little Rock, Little Rock, Arkansas 72205 USA..

Publisher contact information for the American Journal of Hematology is: Wiley-Liss, Division John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA.

Keywords: United States, Little Rock, Hematologic Disease Therapy, Daunorubicin, Drugs, Etanercept, Hematologic Disease, Hematology, Leukemia, Oncology, Pharmaceuticals, Therapy, Treatment.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.